Last reviewed · How we verify
ZYN002 - transdermal gel
ZYN002 - transdermal gel is a cannabinoid Small molecule drug developed by Zynerba Pharmaceuticals, Inc.. It is currently in Phase 3 development for Seizure disorders. Also known as: cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery).
ZYN002, a transdermal gel formulation of cannabidiol, is thought to exert its therapeutic effects through its action on the endocannabinoid system.
ZYN002, a transdermal gel formulation of cannabidiol, is thought to exert its therapeutic effects through its action on the endocannabinoid system. Used for Seizure disorders.
At a glance
| Generic name | ZYN002 - transdermal gel |
|---|---|
| Also known as | cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery) |
| Sponsor | Zynerba Pharmaceuticals, Inc. |
| Drug class | cannabinoid |
| Target | CB2 receptor |
| Modality | Small molecule |
| Therapeutic area | Epilepsy |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of action of cannabidiol is not fully understood, but it is believed to modulate the activity of various receptors in the brain and body, leading to its therapeutic effects. This may involve the inhibition of inflammatory responses, the reduction of pain and anxiety, and the improvement of mood. Further research is needed to fully elucidate the mechanisms by which ZYN002 exerts its effects.
Approved indications
- Seizure disorders
Common side effects
- Application site reactions
- Dizziness
- Somnolence
Key clinical trials
- Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome (INSPIRE) (PHASE2)
- Drug Interaction Study of ZYN002 Transdermal Gel and Probe Substrates (PHASE1)
- Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome (PHASE3)
- Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS (PHASE2, PHASE3)
- Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX) (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZYN002 - transdermal gel CI brief — competitive landscape report
- ZYN002 - transdermal gel updates RSS · CI watch RSS
- Zynerba Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about ZYN002 - transdermal gel
What is ZYN002 - transdermal gel?
How does ZYN002 - transdermal gel work?
What is ZYN002 - transdermal gel used for?
Who makes ZYN002 - transdermal gel?
Is ZYN002 - transdermal gel also known as anything else?
What drug class is ZYN002 - transdermal gel in?
What development phase is ZYN002 - transdermal gel in?
What are the side effects of ZYN002 - transdermal gel?
What does ZYN002 - transdermal gel target?
Related
- Drug class: All cannabinoid drugs
- Target: All drugs targeting CB2 receptor
- Manufacturer: Zynerba Pharmaceuticals, Inc. — full pipeline
- Therapeutic area: All drugs in Epilepsy
- Indication: Drugs for Seizure disorders
- Also known as: cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery)
- Compare: ZYN002 - transdermal gel vs similar drugs
- Pricing: ZYN002 - transdermal gel cost, discount & access